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A computationally assisted approach has enabled the first 
catemeric polymorph of carbamazepine (form V) to be 
selectively formed by templating the growth of 
carbamazepine from the vapour phase onto the surface of a 
crystal of dihydrocarbamazepine form II. 10 
 Why are more polymorphs of organic molecules predicted than 
are observed experimentally?1,2 Either predictive methods 
overestimate the true potential for polymorphism or experimental 
polymorph screens do not sample the appropriate nucleation and 
growth conditions required to encounter all forms. This question 15 
is of particular significance given the importance of controlling 
solid-state structure in many chemical industries, either as a 
means of optimizing a material’s properties3 or to prevent the 
unexpected appearance of a new form during the development of 
a production process.4 A considerable challenge therefore is to 20 
improve upon established approaches to solid form discovery5-7 
to select a specific desired crystal structure from the predicted 
crystal energy landscape (i.e. those computed to be 
thermodynamically feasible). The development of such 
computationally-assisted crystal engineering strategies8,9 would 25 
move experimental crystal form discovery beyond the traditional 
reliance on empiricism and serendipity.  Here we demonstrate 
how computed crystal energy landscapes can be used in this 
manner, specifically, to design a method for producing a specific 
new polymorph (form V†) of the anti-epileptic drug 30 
carbamazepine (CBZ, Fig. 1). 
 
Fig. 1 CBZ and the related molecules 10,11-dihydrocarbamazepine 
(DHC), cyheptamide (CYH) and cytenamide (CYT). 
 CBZ has over 50 reported forms including 4 polymorphs.10-15 35 
The structures of CBZ I, II, III and IV are all based on a 
hydrogen-bonded dimer motif13 and despite extensive 
experimental polymorph searches involving diverse 
approaches,12,15-19 a pure catemeric form of this molecule has 
never been reported.  The strategy leading to the discovery of 40 
CBZ V is based on the selection of an orthorhombic polymorph 
(form II) of the CBZ analogue DHC20 (Fig. 1) as a structural 
template for a predicted, though unobserved, catemer-based form 
of CBZ (see ESI).12, 21   
 In an effort to obtain insights into the crystallization of CBZ 45 
itself, an extended experimental and computational investigation 
into physical form diversity in CBZ12, 21 and the related molecules 
DHC,22,23 CYH24 and CYT25 was carried out.  The computed 
lattice energy landscapes of each molecule4, 12, 23 show that  
structures based on either hydrogen-bonded dimer or catemer 50 
motifs are thermodynamically feasible in every case. The 
experimental investigations, starting from an automated solution 
crystallization screen, produced several new polymorphs21-25 
revealing close structural relationships between the 
experimentally determined structures shown in Fig. 2. 55 
 
Fig. 2 Relationships between experimental forms of DHC, CYH, CYT 
and CBZ.  White and red labels correspond to catemer- and dimer-based 
structures respectively; black arrows identify isostructural relationships, 
including that between DHC II and CBZ V. 60 
 
 To further explore the isostructural relationships that emerged, 
improved lattice energy calculations26 were carried out in which 
the 4 molecules were substituted in turn into each of the 8 distinct 
experimental lattices observed across the series (Fig. 3, details in 65 
ESI). The simulated structure corresponding to CBZ substituted 
in DHC II (i.e. CBZ V), is relatively low on the lattice energy 
plot and comparable in stability with the previously observed 
forms (Fig. 3). 
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 As suggested by these calculations, CBZ V was successfully 
obtained by templating growth of CBZ from the vapour phase 
onto the surface of a DHC II crystal. 50 mg of CBZ III was 
placed in a 10 mL glass vial and a single crystal of DHC II was 
attached to a copper wire and suspended 1-2 cm above the CBZ. 5 
The sealed vial was placed onto a hot-plate at 125 °C for 24-48 
hours. CBZ crystals formed by reverse sublimation onto the 
surface of the seed and these crystals were removed and 
identified by single-crystal X-ray diffraction.  Crystals that grew 
on the seed always formed on the smallest edge faces of the 10 
crystal (Fig. 4) whilst those that grew on the wire or inside walls 
of the vial were either CBZ I or III. The crystal structure of form 
V is catemeric (Fig. 5, ‡) and is isostructural with DHC II and the 
simulated CBZ structure (see ESI).   
 15 
Fig. 3 Lattice energy substitution calculations for CBZ, CYT, CYH and 
DHC in the 8 distinct crystal structure types observed experimentally 
(Fig. 2). The colour of each symbol denotes the molecule (CBZ – yellow, 
CYH – pink, CYT – green and DHC – grey) and the symbol represents 
the lattice. Each substitution that matches an observed form is highlighted 20 
as an open box, with CBZ V in a double red box. 
Fig. 4 DHC II seed crystal with thin plates of CBZ V (i-iii) emerging 
from the edge faces. 
 
 The formation of this specific CBZ polymorph, achieved by 25 
combining experimental and computational studies of 
polymorphic diversity in related molecules, has thus verified the 
initial computational predictions that catemeric forms of CBZ are 
feasible. Further work on this and other molecular families is 
required to assess the general transferability of this 30 
computationally-assisted approach to polymorph screening by 
lattice energy calculations on isomorphous structures and to 
define the templating mechanism in detail. 
 
Fig. 5 Single crystal structure of CBZ V showing the catemeric hydrogen 35 
bonded motif extending in the direction of the a-axis. 
Form V CBZ represents a significant advance in polymorph 
discovery and control in that it did not result from the facile 
extension of experimental crystallization search space for the 
molecule, but rather by computer-aided exploration of the 40 
polymorphs of related molecules to find a template. This 
approach of combining crystal energy landscape prediction, 
experimental screening, and lattice energy substitution 
calculations illustrates a strategy to increase the probability that 
all practically important long-lived polymorphs are discovered.  45 
In so doing, these methods offer a new paradigm in the control 
and selection of solid-state properties of pharmaceuticals and 
other speciality chemicals. 
Conclusions 
 A predicted catemeric polymorph of CBZ has been produced 50 
experimentally by exploiting the 3D similarity between computed 
and experimental structures of closely related molecules to find a 
solid-state template. The fact that form V CBZ has not been 
observed before, despite extensive polymorph screening, 
emphasizes the need for caution in concluding that unobserved 55 
thermodynamically feasible structures cannot appear. In the case 
of CBZ at least, it would seem that previous experimental 
searches provided insufficient coverage of the experimental 
crystallization space to allow the formation of this polymorph.  
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‡ Diffraction data were collected at 123 K from a CBZ V crystal 
measuring 0.12 × 0.08 × 0.04 mm using Cu Kα radiation (λ = 1.54180 Å), 
measured reflections = 5416, independent reflections = 2140, θmax = 
72.8819, Rint = 0.0624, R = 0.0461, wR = 0.0925. Orthorhombic, space 
group Pbca, unit cell parameters a = 9.1245(5), b = 10.4518(5), c = 5 
24.8224(11) Å, volume = 2367.2(2) Å3; Z = 8, ρcalcd = 1.326 g cm-3, 
C15H12N2O, Mr = 236.3. 
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Figure S1. ORTEP diagram of CBZ form V (ellipsoids at 50% probability level) 
Figure S2. Generalized molecular structure of CBZ/DHC/CYH/CYT, showing the torsion angles whose structures 
were varied within the lattice energy minimization.   
 
 




1. Single-Crystal Structure analysis of CBZ form V 
Data for this crystal structure were measured at 123 K with graphite monochromated Cu Kα radiation (λ = 1.54180 Å) 
using an Oxford Diffraction Gemini S instrument. All non hydrogen atoms were refined anisotropically. Hydrogen 
atoms of the amide group were refined isotropically, whereas other H atoms were placed in calculated positions 
utilizing riding modes. All structures were refined to converge against F2 using the SHELXL-97 program.1  A 
summary of data collection and refinement details is provided in Table S1. The asymmetric unit of CBZ form V is 
shown in Figure S1. 
Table S1: Crystallographic details of CBZ form V structure 
Compound reference Carbamazepine form V 
Chemical formula C15H12N2O 
Formula Mass 236.27 







Unit cell volume/Å3 2367.2(2) 
colour Colourless 
Temperature/K 123(2) 
Space group Pbca 
No. of formula units per unit cell, Z 8 
No. of reflections measured 5416 
No. of independent reflections 2140 
Rint 0.0624 
Final R1 values (I > 2σ(I)) 0.0461 
Final wR(F2) values (I > 2σ(I)) 0.0946 
Final R1 values (all data) 0.0872 
Final wR(F2) values (all data) 0.1047 
Goodness of fit on F2 0.816 
 
 




Figure S1. ORTEP diagram of CBZ form V (ellipsoids drawn at 50% probability level). 
 
 
Table S2. Unit cells for CBZ form V, CBZ:DHC 50:50 solid-solution, DHC II and predicted CBZ structure. 
Compound reference CBZ form V DHC form II2 50:50 solid solution3 Predicted 4  
Crystal system Orthorhombic Orthorhombic Orthorhombic Orthorhombic 
a/Å 9.1245(5) 9.0592(4) 9.088(2) 9.312 
b/Å 10.4518(5) 10.3156(5) 10.425(4) 10.598  
c/Å 24.8224(11) 25.0534(12) 25.005(7) 24.882 
α/° 90.00 90.00 90 90 
β/° 90.00 90.00 90 90 
γ/° 90.00 90.00 90 90 
Unit cell volume/Å3 2367.2(2) 2341.3 2369.0 2455.6 
Temperature/K 123(2) 120 150 0 




















Figure S2. Generalized molecular structure of CBZ/DHC/CYH/CYT, showing the torsion angles whose structures 
were varied within the lattice energy minimization.   
The atomic coordinates of hypothetical crystal structures were generated by substituting molecular structures so as to 
minimize the root-mean-square deviations of all atoms except hydrogens, with the C atom in CYH or CYT being 
matched to the N atom in CBZ or DHC.  CYH and DHC have two low energy conformations differing in the 
orientation of the carboxamide group relative to the C10–C11 bond, both of which are observed in crystal structures. 
(The lower energy anti-conformer is observed in DHC I, II and III and the known solvate structures except that of the 
disordered DHC:DMSO, in which both the anti- and syn-conformers are both present with fractional occupancies of 
0.81 and 0.19 respectively. The catemeric DHC form IV contains the syn-conformer.5   CYH form II contains 3 
molecules in the lower energy anti conformation and one in the syn conformation.) Hence, hypothetical structures 
containing both conformations were considered. The exception was the hypothetical structure of DHC in the Z’=4 
CBZ I structure, where the conformations seen in the structural isomer CYH II were assumed. 
The CrystalOptimizer algorithm6 was used to simultaneously optimise the crystal structure and the molecular 
conformation within it by  minimizing the lattice energy Elatt=Uinter+∆Eintra. Only the torsion angles (Fig S2) defining 
the two amide hydrogen positions, the rotation of the amide group with respect to the 7-membered ring, the angle of 
the amide to the ring, and, for CYH and DHC, the twist of the saturated bond of the 7-membered ring, were explicitly 
optimised within the crystal structure: all other intramolecular variables were defined by the constrained isolated 
molecule ab initio optimization. The intramolecular energy penalty for the conformational changes from the ab initio 
optimized structure, ∆Eintra, was calculated using GAUSSIAN03 at the RHF level of theory, with the 6-31G(d,p) basis 
set.  The intermolecular lattice energy, Uinter,  was calculated by DMACRYS using an isotropic atom-atom exp-6 
potential with the FIT parameters7 and all terms in the electrostatic energy up to R-5 calculated from the atomic 
multipoles up to hexadecapole. The atomic multipoles were obtained using GDMA28 to analyse the MP2/ 6-31G(d,p) 
charge density. The resulting lattice energy minima are shown in Table S3, and on Figure 3. 
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Table S3. Comparison of the experimental and lattice energy minima for the observed and computationally generated isostructural crystal structures of the CBZ family (Fig. 3) 














/ kJ mol-1 
Uinter 
/ kJ mol-1 
∆Eintra 
/ kJ mol-1 
Density 
/ g cm-3 
CBZI CBZ CBZI P-1 5.171(<1) 20.574(2) 22.245(2) 84.12(<1) 88.01(<1) 85.19(<1)    1.339 
    5.262 20.517 22.365 85.160 86.361 85.932 -124.804 -127.440 2.636 1.310 
 CYT CYTII P-1 5.810(<1) 19.632(<1) 21.709(<1) 85.92(<1) 86.16(<1) 84.48(<1)    1.274 
    5.641 19.937 21.891 86.126 84.945 84.868 -129.618 -131.132 1.514 1.282 
 CYH CYHII P-1 5.649(<1) 19.564(<1) 22.074(<1) 84.22(<1) 88.41(<1) 83.60(<1)    1.307 
    5.727 19.874 22.136 84.163 88.313 83.761 -129.679 -130.698 1.019 1.265 
 DHC hypothetical           
    5.442 21.179 22.430 83.763 89.522 86.076 -111.260 -113.955 2.694 1.235 
CBZII CBZ CBZII R-3 35.454(3) 35.454(3) 5.253(1) 90 90 120    1.235 
   R-3 35.423(5) 35.243(5) 5.185(1) 90 90 120    1.305 
    35.264 35.264 5.272 90 90 120 -121.971 -125.343 3.372 1.244 
 CYT CYTI R-3 33.908(1) 33.908(1) 5.675(<1) 90 90 120    1.244 
    34.249 34.249 5.639 90 90 120 -127.958 -128.759 0.802 1.228 
 CYH hypothetical           
  anti  34.378 34.378 5.637 90 90 120 -126.458 -128.168 1.709 1.229 
  syn  35.743 35.743 5.666 90 90 120 -121.497 -123.080 1.582 1.131 
 DHC hypothetical           
  anti  35.140 35.140 5.433 90 90 120 -118.406 -120.796 2.390 1.226 
  syn  36.072 36.072 5.461 90 90 120 -115.485 -118.506 3.021 1.157 
CBZIII CBZ CBZIII P21/n 7.537(1) 11.156(2) 13.912(3) 90 92.86(2) 90    1.343 
    7.885 11.018 13.427 90 87.706 90 -128.755 -130.265 1.511 1.346 
 CYT hypothetical           
    6.768 11.657 16.993 90 112.179 90 -101.682 -102.132 0.450 1.259 
 CYH hypothetical           
  anti  7.671 11.871 13.789 90 87.682 90 -114.721 -118.498 3.777 1.256 
  syn  7.572 11.710 14.115 90 91.072 90 -118.974 -121.928 2.954 1.260 
 DHC hypothetical           
  anti  7.547 11.612 13.986 90 91.382 90 -121.192 -123.028 1.836 1.292 
  syn  7.804 11.736 13.545 90 94.080 90 -119.369 -121.424 2.055 1.279 
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CBZIV CBZ CBZIV C2/c 26.609(4) 6.927(1) 13.957(2) 90 109.70(<1) 90    1.296 
    26.856 6.916 25.429 90 31.853 90 -123.250 -124.976 1.727 1.259 
 CYT hypothetical           
    29.464 7.334 13.597 90 121.236 90 -105.296 -108.650 3.354 1.244 
 CYH hypothetical           
  anti  28.422 7.616 13.947 90 120.231 90 -104.606 -108.523 3.917 1.208 
  syn  27.442 6.317 15.441 90 108.273 90 -118.540 -121.668 3.128 1.240 
 DHC hypothetical           
  anti  25.781 7.806 13.626 90 116.457 90 -120.992 -124.535 3.544 1.289 
  syn  24.354 8.150 13.516 90 103.381 90 -112.775 -117.662 4.887 1.213 
DHCI CBZ hypothetical           
    5.061 9.299 26.290 90 102.869 90 -122.075 -123.819 1.743 1.301 
 CYT hypothetical           
    5.500 9.218 24.666 90 99.697 90 -119.463 -124.010 4.547 1.268 
 CYH CYHI P21/c 5.604(<1) 9.172(1) 23.579(3) 90 96.75(1) 90    1.310 
    5.545 9.467 23.458 90 98.309 90 -135.238 -136.083 0.845 1.294 
 DHC DHCI P21/c 5.505(1) 9.158(2) 24.266(7) 90 95.95(2) 90    1.301 
    5.363 9.506 23.963 90 94.382 90 -130.002 -130.774 0.772 1.299 
DHCII CBZ CBZV Pbca 9.1245(5) 10.4518(5) 24.8224(11) 90 90 90    1.326 
    9.517 10.245 24.833 90 90 90 -124.689 -125.496 0.808 1.296 
 CYT hypothetical           
    9.210 11.460 23.374 90 90 90 -125.078 -125.221 0.143 1.267 
 CYH hypothetical           
  anti  9.282 10.849 24.126 90 90 90 -131.811 -133.389 1.578 1.298 
  syn  9.421 11.238 24.597 90 90 90 -116.834 -119.551 2.717 1.210 
 DHC DHCII Pbca 9.059(<1) 10.316(<1) 25.053(1) 90 90 90    1.352 
    9.281 10.467 24.718 90 90 90 -131.368 -132.044 0.676 1.318 
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DHCIII CBZ hypothetical           
    5.062 9.299 26.286 90.001 77.138 90.041 -122.069 -123.803 1.733 1.301 
 CYT hypothetical           
    5.505 9.220 25.251 89.968 74.182 90.198 -119.441 -123.907 4.466 1.267 
 CYH hypothetical           
  anti  7.044 8.681 22.580 80.243 83.326 71.604 -117.435 -118.976 1.541 1.224 
  syn  5.656 8.516 28.515 88.383 73.451 90.318 -114.020 -115.009 0.989 1.198 
 DHC DHCIII P-1 5.423(1) 9.200(5) 24.189(6) 87.59(3) 84.23(2) 88.93(3)    1.319 
    5.363 9.515 24.139 89.998 81.521 89.980 -130.014 -130.704 0.690 1.299 
DHCIV CBZ hypothetical           
    14.261 4.990 18.610 90 112.232 90 -121.463 -121.777 0.314 1.280 
 CYT hypothetical           
    12.709 5.586 18.625 90 106.600 90 -122.670 -123.928 1.258 1.233 
 CYH hypothetical           
  anti  11.637 7.001 16.726 90 99.472 90 -115.415 -117.066 1.651 1.173 
  syn  13.445 5.554 18.118 90 104.728 90 -121.734 -123.090 1.356 1.205 
 DHC DHCIV P21/c 13.207(6) 5.347(2) 18.891(7) 90 116.37(2) 90     
    13.246 5.418 18.853 90 115.587 90 -126.921 -132.204 5.283 1.297 
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A combined computational and experimental strategy has produced the first polymorph of carbamazepine (form 
V) that displays a catemeric hydrogen bonding motif.  
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